TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01611051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Pegylated rhG-CSF: 100µg/kg
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF: 6mg
Description: Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF 5ug/kg/day
Description: Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
Study: NCT00552630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: d-penicillamine
Description: d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo with same characteristics as drug
Study: NCT00868218

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14
Study: NCT00410826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 35 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: 35 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: 35 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: intensity-modulated radiation therapy
Description: 35 fractions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT00785551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324mg given in one dose to healthy subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324mg given as one dose to subjects with mild renal impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinine sulfate
Description: 2 x 324mg given as one dose to subjects with moderate renal impairment
Study: NCT04416529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-MBCT
Description: Please see arm/group description.
Study: NCT04535713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg i.v. on Day 1 beginnning Cycle 2+
Study: NCT01342965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib was supplied as tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin and gemcitabine were locally sourced with commercial products.
Study: NCT02306304

Intervention type: OTHER
Group type: OTHER
Intervention: Duplex ultra sound screening for abdominal aortic aneurysms
Description: Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
Study: NCT04783649

Intervention type: DIAGNOSTIC_TEST
Intervention: Papanicolaou cytological test
Description: Cervical smear stained using conventional Papanicolaou technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Papanicolaou cytological test
Description: Cervical smear stained using conventional Papanicolaou technique.

Intervention type: DIAGNOSTIC_TEST
Intervention: Local cytological test (H&E stain)
Description: Cervical smear stained using conventional hematoxylin and eosin staining techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Local cytological test (H&E stain)
Description: Cervical smear stained using conventional hematoxylin and eosin staining techniques

Intervention type: DIAGNOSTIC_TEST
Intervention: Validated HPV DNA Test
Description: Digene HC2 HPV DNA Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Validated HPV DNA Test
Description: Digene HC2 HPV DNA Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Local HPV test
Description: RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Local HPV test
Description: RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Colposcopy
Description: Women with positive cytology results are referred to colposcopy and biopsy
Study: NCT01274780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir / Ritonavir + Tenofovir / Emtricitabine
Description: oral, 800/100 mg, qd + oral, 300/200 mg, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir / Ritonavir + Tenofovir / Emtricitabine
Description: oral, 300/100 mg, qd + oral, 300/200 mg, qd
Study: NCT02813642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma osteoprotegerin level
Description: dosage of plasma osteoprotegerin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma fibroblast growth factor 23 level
Description: dosage of plasma fibroblast growth factor 23

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular calcification score
Description: measurement of vascular calcification score by X-ray of the lateral abdominal aorta
Study: NCT00603070

Intervention type: OTHER
Intervention: E-prescribing system
Description: Transition from home-grown to vendor-based ambulatory e-prescribing systems

Intervention type: OTHER
Intervention: Electronic transmission of medication discharge lists
Description: Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
Study: NCT00681980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: 15 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: costicosteroids
Description: metypredsolone 1 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproid acid plus corticosteroids
Description: valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
Study: NCT00350623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)
Description: 3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)
Description: 3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)
Description: 3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
Study: NCT04126564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inner Engineering Online
Description: Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inner Engineering Online
Description: Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading a book/ journal
Description: Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
Study: NCT01069107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cottage Hospital Care
Description: Care at a cottage hospital compared with care at a general hospital
Study: NCT00074087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Study: NCT03032367

Intervention type: DRUG
Group type: OTHER
Intervention: bedaquiline

Intervention type: DRUG
Group type: OTHER
Intervention: bedaquiline
Study: NCT02723032

Intervention type: DEVICE
Group type: OTHER
Intervention: OxyFrame
Description: Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
Study: NCT04793243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Patients received oral supplementation of 10,000 IU daily for fourteen days of vitamin D3
Study: NCT00997906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin,
Description: Given IV
Study: NCT02020876

Intervention type: OTHER
Intervention: DECIPHER Questionnaire
Description: Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
Study: NCT04081961

Intervention type: DEVICE
Intervention: Anamed OEM device; Air Next mobile spirometry device
Description: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device

Intervention type: DEVICE
Intervention: Anamed OEM device; Air Next mobile spirometry device
Description: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device

Intervention type: DEVICE
Intervention: Anamed OEM device; Air Next mobile spirometry device
Description: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
Study: NCT04543890

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Thoracic radiotherapy (45 Gy/15 fractions) for the Hypofractionated Arm and prophylactic cranial irradiation (25 Gy/10 fractions).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
Study: NCT02254785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone 1000mg daily (oral) until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide 160mg daily (oral)
Description: Enzalutamide 160mg daily (oral) until disease progression
Study: NCT03445910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin
Description: intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
Study: NCT06495840

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00723866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BtxA+mCIMT
Description: The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BtxA+ conventional rehabilitation
Description: The control group received for 2 hours/day, 3 days/week for 3 months.
Study: NCT01572909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendavia (MTP-131)
Description: 0.05 mg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing placebo
Study: NCT04543890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Study: NCT01089959

Intervention type: DRUG
Group type: OTHER
Intervention: Esomeprazole
Description: 40 mg daily for 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole
Description: 40 mg. daily, oral medication, once daily for 7 days.
Study: NCT02703909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
Study: NCT04543890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Study: NCT02656888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irlanda-1-Association
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
Study: NCT01130597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patiromer
Description: Active investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Study: NCT00606164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin for Injection
Description: A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin for Injection
Description: A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single one-hour intravenous infusion of placebo on Day 1
Study: NCT02518672

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MAG-DHA
Description: MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
Study: NCT04496284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitrification via slush nitrogen
Description: blastocyst stage embryos will be vitrified via slush nitrogen
Study: NCT03997617

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Personalized Functional Profiling
Description: During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
Study: NCT01793948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00738764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDL192
Description: Humanized anti-TWEAK receptor monoclonal IgG1 antibody
Study: NCT02703909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation pressure
Description: The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation pressure
Description: The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insufflation pressure
Description: The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insufflation pressure
Description: The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
Study: NCT00410046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel (etanercept)
Description: Etanercept 50 mg SC injection once weekly
Study: NCT01479153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization of the site for catheterization
Description: Ultra-sound guided insertion strongly recommended

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization of the site for catheterization
Description: Ultra-sound guided insertion strongly recommended

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomization of the site for catheterization
Description: Ultra-sound guided insertion strongly recommended
Study: NCT01059786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentostatin
Description: 28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: 28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
Study: NCT00948324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII,ALA,MET,RSG
Description: CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII,ALA,MET,RSG
Description: CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII,ALA,MET,RSG
Description: CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII,ALA,MET,RSG
Description: CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
Study: NCT01998724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 24 week tai chi intervention designed for individuals with COPD